2.5 Hereditary Cancer Syndromes & Genetic Counseling

2.1 Hereditary Cancer Syndromes & Genetic Counseling

Clinical Pearl: Differentiating germline from somatic variants is essential in APRN clinical practice. A germline variant is inherited from a parent, present in all constitutional cells, and transmissible to offspring, whereas somatic testing evaluates acquired mutations isolated within tumor tissue to guide targeted therapy selection (e.g., PARP inhibitors or immune checkpoint inhibitors).

Principles of Cancer Genetics & Inheritance Patterns

Approximately 5% to 10% of all adult malignancies arise directly from inherited high-penetrance germline gene mutations, with an additional 15% to 20% exhibiting familial clustering due to low-penetrance polygenic variants and shared environmental exposures. Most hereditary cancer syndromes follow an autosomal dominant pattern of inheritance, characterized by a 50% risk of transmission to offspring regardless of biological sex.

At the cellular level, tumor suppressor gene mutations follow Knudson's Two-Hit Hypothesis: individuals inherit a first "hit" (a germline pathogenic variant) in every cell, requiring only a second somatic mutation or epigenetic inactivation of the remaining wild-type allele to initiate oncogenesis. High-penetrance germline mutations display variable expressivity and incomplete penetrance, meaning not all mutation carriers develop malignancy, though their relative risk is dramatically elevated above population baselines.

Summary of Major Hereditary Cancer Syndromes

---

Major Hereditary Cancer Syndromes in APRN Practice

Hereditary Breast and Ovarian Cancer (HBOC) Syndrome

BRCA1 (chromosome 17q) and BRCA2 (chromosome 13q) are critical tumor suppressor genes encoding proteins involved in homologous recombination repair (HRR) of DNA double-strand breaks. Germline pathogenic variants in BRCA1 confer a lifetime risk of female breast cancer of 55%–72% and ovarian cancer risk of 39%–44%. Germline BRCA2 mutations confer a female breast cancer risk of 45%–69%, an ovarian cancer risk of 11%–17%, and notably elevated risks for male breast cancer (up to 7–10%), prostate cancer (especially aggressive Gleasongrade ≥8), and pancreatic ductal adenocarcinoma.

Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer)

Lynch syndrome is caused by germline mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) or epigenetic silencing of MSH2 via EPCAM deletion. MMR deficiency leads to uncorrected replication slippage errors in repetitive DNA sequences, resulting in microsatellite instability-high (MSI-H) phenotypes. Colorectal cancer in Lynch syndrome characteristically presents in the right/proximal colon at an early median age (44–50 years). Women with Lynch syndrome face a lifetime endometrial cancer risk (20%–60%) that equals or exceeds their colorectal cancer risk, particularly with MSH2 and MSH6 mutations.

Rare High-Penetrance Syndromes

• Li-Fraumeni Syndrome (TP53): Characterized by early-onset sarcomas, breast cancer, brain tumors, adrenocortical carcinoma, and leukemias. Diagnostic evaluation requires avoiding ionizing radiation (CT scans, X-rays, radiotherapy) whenever possible due to heightened radio-induced secondary malignancy risk.
• Cowden Syndrome (PTEN): Marked by dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease), macrocephaly, trichilemmomas, and high lifetime risks for breast (85%), thyroid (35%), and endometrial (28%) cancers.
• Familial Adenomatous Polyposis (APC): Characterized by hundreds to thousands of colorectal adenomatous polyps developing during adolescence. Without prophylactic total colectomy, colorectal cancer risk approaches 100% by age 40.

---

NCCN Genetic Testing Criteria & Counseling Workflow

The Advanced Practice Registered Nurse plays a vital role in identifying candidate patients, obtaining structured family pedigrees (minimum 3 generations), facilitating pre-test counseling, and executing post-test clinical management.

Patient Identification (Personal/Family History meets NCCN criteria)
  │
  ▼
Pre-Test Genetic Counseling & Informed Consent
  ├─ 3-Generation Pedigree Analysis
  ├─ Discussion of Benefits, Limitations, and VUS Potential
  └─ Review of GINA Protections & Insurance Coverage
  │
  ▼
Multi-Gene Next-Generation Sequencing (NGS) Panel
  │
  ├─────────────────────────┼─────────────────────────┐
  ▼                         ▼                         ▼
Pathogenic Variant       Negative Result           Variant of Uncertain
Identified               (True vs Uninformative)   Significance (VUS)
  │                         │                         │
  ├─ Medical Management     ├─ Manage based on        ├─ Do NOT base surgical
  │  (Risk Reduction)       │  family pedigree        │  decisions on VUS
  └─ Cascade Testing for    └─ Re-evaluate in 3-5 yrs └─ Manage per family
     1st-Degree Relatives                             history & re-classify

Pre-Test Genetic Counseling & Medical-Legal Considerations

Pre-test counseling must address the psychological impact of genetic results, potential financial implications, and the Genetic Information Nondiscrimination Act (GINA). GINA prohibits federal health insurance providers and employers (with ≥15 employees) from requesting genetic testing or using genetic results to deny coverage or determine employment status. However, GINA does not cover life insurance, disability insurance, or long-term care insurance—a key distinction for APRNs to clarify prior to ordering tests.

Test Selection & Result Interpretation

Modern evaluation utilizes multi-gene Next-Generation Sequencing (NGS) panels. Results fall into three categories:

1. Positive (Pathogenic/Likely Pathogenic Variant): Confirms hereditary risk; dictates specific surveillance and risk-reducing interventions; triggers cascade testing (offering targeted single-site variant testing to first-degree blood relatives).
2. Negative: If a known familial mutation exists, a negative result is a "true negative" (individual returned to general population risk). If no familial mutation was previously identified, it is an "uninformative negative," and management defaults to clinical and family history risk models (e.g., Tyrer-Cuzick, Claus).
3. Variant of Uncertain Significance (VUS): A DNA sequence alteration whose clinical effect on protein function is unknown. CRITICAL EXAM RULE: A VUS must never be used to direct risk-reducing surgeries (e.g., prophylactic mastectomy or oophorectomy). Medical management must be guided solely by personal and family history while the variant undergoes periodic reclassification.

---

Surveillance & Risk-Reduction Interventions

Management of high-risk mutation carriers integrates intensified screening, surgical risk reduction, and chemoprevention:

• Surgical Risk Reduction: Risk-Reducing Salpingo-Oophorectomy (RRSO) decreases all-cause mortality and ovarian cancer incidence by >80–90% in BRCA1/2 carriers. In BRCA1 carriers, RRSO is recommended between ages 35 and 40 upon completion of childbearing; in BRCA2, between ages 40 and 45. Risk-Reducing Mastectomy (RRM) reduces breast cancer risk by >90% in HBOC.
• Chemoprevention: Selective Estrogen Receptor Modulators (tamoxifen, raloxifene) or aromatase inhibitors (in postmenopausal women) reduce invasive breast cancer incidence in high-risk women by 38%–50%. Daily low-dose aspirin reduces long-term colorectal cancer incidence in Lynch syndrome carriers.
• Targeted Therapeutics: Identification of germline BRCA1/2 or MMR deficiency directly alters systemic antineoplastic therapy. PARP inhibitors (e.g., olaparib, rucaparib) leverage synthetic lethality in HRR-deficient tumor cells, demonstrating marked activity in germline BRCA-mutated HER2-negative breast, pancreatic, ovarian, and prostate cancers. Similarly, MSI-H/dMMR status predicts profound response to anti-PD-1 immune checkpoint inhibitors (e.g., pembrolizumab).